Mr. Yang Gao | Cholangiocarcinoma | Best Researcher Award

Posted on by Pencis

Mr. Yang Gao | Cholangiocarcinoma | Best Researcher Award

Tongji Medical College Huazhong University of Science and Technology | China

Author Profile

Scopus

šŸ“˜ Dr. Yang Gao: A Dedicated Leader in Hepatobiliary Oncology Research

Full Name: Yang Gao

Gender: Male

Designation: Attending Doctor; Lecturer

Department: Department of Hepatobiliary Surgery

Institution/Organization: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

Qualification: Doctor (MD, PhD)

Area of Specialization: Hepatobiliary Oncology and Cancer

Sub Division: Oncology Therapeutics and Novel Approaches

Date of Birth: October 25, 1987

Onboard Date: July 1, 2018

Total Experience:

  • Work: 5 years
  • Doctor: 3 years
  • Master: 3 years
  • Bachelor: 5 years

Contact Information:

šŸŽ“ Education and Training

  • 2015.09-2018.06: MD, PhD in Hepatobiliary Surgery from Tongji Medical College, Huazhong University of Science and Technology
  • 2012.09-2015.06: Masterā€™s in Hepatobiliary Surgery from Tongji Medical College, Huazhong University of Science and Technology
  • 2007.09-2012.06: Bachelorā€™s in Clinical Medicine from Shandong Second Medical University

šŸ„ Professional Experience

2018.07 – Present: Attending Physician and Lecturer at the Affiliated Union Hospital of Tongji Medical College, Huazhong University of Science and Technology.

  • Proficient in surgical treatments for benign and malignant tumors of the liver and gallbladder, including gallstones.
  • Expert in minimally invasive laparoscopic surgery, especially for liver cancer, anatomical liver resection surgery, and complex biliary surgeries.
  • Skilled in the comprehensive treatment of hepatocellular carcinoma and biliary tract cancer, including intervention, targeting, and immunotherapy.

šŸ“Š Research, Innovations, and Extensions

  • Research Projects Completed and Ongoing: 6
  • Citation Index in Scopus/Web of Science/PubMed: 61
  • Total Project Cost: $414,000 USD
  • Patents: 5 published and under process
  • Journals Published (SCI and SCIE index): 12
  • Journals Published (Scopus/Web of Science/PubMed index): 13
  • Countries Visited for Research: 1
  • Cumulative Impact Factor (last 3 years): 55
  • H-index: 5
  • Invited Speaker/Resource Person: 1
  • Member of Professional Bodies: 10

šŸ† Awards and Recognitions

  • Total Number of Awards and Recognitions: 1
  • Award Category: Best Researcher Award

šŸŒ Contribution to Research & Development, Innovations, and Extension Activities On Cholangiocarcinoma

Dr. Yang Gao has significantly contributed to the field of Tumor Research & Development, Innovations, and Extension Activities. His work focuses on advancing the understanding of tumor biology, therapeutic interventions, and patient care outcomes, particularly in hepatobiliary malignancies. Dr. Gao collaborates with interdisciplinary teams to discover novel biomarkers, therapeutic targets, and treatment modalities aimed at improving patient outcomes and quality of life.

Dr. Gao has played a pivotal role in translating research findings into clinical practice by fostering partnerships with industry stakeholders, academic institutions, and healthcare providers. His efforts have led to the development and implementation of cutting-edge technologies and treatment approaches in oncology.

Moreover, Dr. Gao actively engages in extension activities to disseminate knowledge and promote cancer prevention, early detection, and treatment options within the community. Through educational workshops, public seminars, and outreach programs, he empowers patients, caregivers, and healthcare professionals with the information and resources needed to combat cancer effectively. His dedication to cancer research, innovation, and community outreach underscores his commitment to making a meaningful impact in the fight against cancer.

šŸ“œ Personal and Research Proofs

  • Institute ID Number: 2018XH0171
  • Certificate Number (Education Proof): 1048722018100647
  • Passport Number: E28938966
  • Government ID: 370181198710251116

āœ… Declaration

Dr. Yang Gao, authenticate that to the best of my knowledge, the information given in this form is correct and complete. If any material information is found to be concealed, my application shall be summarily terminated without notice. I have read and agree to the terms and conditions and other policies of the International Research Awards.

Notable Publication

    • Authors: Yang Gao, et al.
    • Journal: Journal of Hepatology Research
    • Volume: 35
    • Year: 2021

 

 

    • Authors: Yang Gao, et al.
    • Journal: Cancer Research
    • Volume: 80
    • Year: 2022

 

    • Authors: Yang Gao, et al.
    • Journal: Annals of Surgery
    • Volume: 270
    • Year: 2021

 

    • Authors: Yang Gao, et al.
    • Journal: International Journal of Surgery
    • Volume: 76
    • Year: 2020

Prof. IsabellaCavalcanti – Cancer Science – Best Researcher Award

Posted on by Pencis

Prof. IsabellaCavalcanti - Cancer Science - Best Researcher Award

Federal University of Pernambuco (UFPE) - Brazil

Author Profile

Google ScholarĀ 

Scopus

Orcid

EARLY ACADEMIC PURSUITS

Isabella MacƔrio Ferro Cavalcanti began her academic journey by graduating in Biomedicine from the Federal University of Pernambuco (UFPE). Following this, she pursued a master's degree in Therapeutic Innovation at UFPE, delving into advanced studies in the field. She then proceeded to earn her doctorate in Biotechnology, further refining her expertise in biological sciences.

PROFESSIONAL ENDEAVORS

Dr. Cavalcanti's professional career has been marked by significant accomplishments. She specializes in Clinical Microbiology, obtaining further specialization at the University of Pernambuco (UPE). Currently, she serves as a professor at UFPE, where she contributes to the education and training of future professionals in the field. Her involvement extends to leadership roles within various post-graduate programs, emphasizing her dedication to academic advancement.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER SCIENCE

Dr. Cavalcanti's research endeavors are diverse and impactful. As the Head and Researcher of Clinical Microbiology at the Laboratory of Immunopathology Keizo Asami at UFPE (LIKA/UFPE), she spearheads investigations into drug delivery systems and their biological activities. Her research group, MicroNAT, focuses on innovative approaches to combat multi-drug-resistant bacteria and biofilm formation. Through her work, she seeks to advance pharmaceutical nanotechnology and fundamental microbiological understanding.

IMPACT AND INFLUENCE

Isabella MacƔrio Ferro Cavalcanti's contributions have had a profound impact on the fields of pharmaceutical nanotechnology and microbiology. Her research findings contribute to the development of novel therapeutic strategies and the understanding of microbial resistance mechanisms. As a respected member of the Brazilian Society of Microbiology and various scientific committees, her expertise is recognized nationally and internationally.

ACADEMIC CITATIONS

Dr. Cavalcanti's work has garnered significant attention within the academic community, reflected in numerous citations of her research publications. Her contributions to scientific literature serve as a foundation for further exploration and innovation in the fields of biotechnology, microbiology, and drug delivery.

LEGACY AND FUTURE CONTRIBUTIONS

With a strong foundation in academia and research, Dr. Cavalcanti's legacy is marked by her dedication to advancing knowledge and addressing critical healthcare challenges. Her leadership in research groups and academic programs ensures the continued development of future scientists and the pursuit of innovative solutions to complex biomedical problems. As she continues her career, her contributions are poised to further shape the landscape of biomedicine and microbiology, leaving a lasting legacy of excellence and innovation.

NOTABLE PUBLICATIONS

Zein nanoparticles containing ceftazidime and tobramycin: antibacterial activity against Gram-negative bacteria. 2024

Proteomic characterization and biological activities of the mucus produced by the zoanthid Palythoa caribaeorum (Duchassaing & Michelotti, 1860) 2023

Efficacy and non-toxicity of ciclopirox olamine-loaded liposomes against Cryptococcus neoformans clinical isolates. 2023

Gram-negative bacilli carrying mcr gene in Brazil: a pathogen on the rise. 2023

Antibiotic resistance profiles on pathogenic bacteria in the Brazilian environments. 2023

Ms. Hao Li – Tumor Immunology – Young Scientist Award

Posted on by Pencis

Ms. Hao Li - Tumor Immunology - Young Scientist Award

First Hospital of China Medical University - China

Author Profile

Scopus

EARLY ACADEMIC PURSUITS

Li Hao began his academic journey at Dalian Medical University in September 2015, majoring in Immunology, Biochemistry, Surgery, and Internal Medicine. During this period from 2015 to 2020, he laid the foundational knowledge in the medical sciences that would serve as the basis for his future specialization. His undergraduate studies provided him with a comprehensive understanding of the human body's immune system, biochemistry, surgical techniques, and internal medicine.Li Hao pursued his Master's degree in Emergency Medicine and Molecular Biology at China Medical University. This advanced academic pursuit enabled him to delve deeper into specialized areas of medicine, focusing on emergency care and the molecular mechanisms underlying various medical conditions.

PROFESSIONAL ENDEAVORS

In May 2021, Li Hao started his professional career as a Resident Physician at the First Hospital of China Medical University. During his tenure from May 2021 to August 2021, he gained hands-on experience in clinical settings, honing his skills in medical records writing and cardiopulmonary resuscitation (CPR). This role allowed him to apply his theoretical knowledge from his undergraduate studies in a practical setting, preparing him for more specialized roles in the medical field.In June 2023, Li Hao transitioned to the role of an Assistant at the First Hospital of China Medical University, where he continues to work to the present day. As an Assistant, he has been involved in research projects and clinical work, further expanding his expertise and contributing to advancements in the medical field.

CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR IMMUNOLOGY

Li Hao's research interests are diverse and interdisciplinary, focusing on the areas of nanomaterials, hepatocellular carcinoma, and macrophage biology. His research aims to explore innovative approaches and treatments for these medical conditions, leveraging the latest advancements in molecular biology and emergency medicine.

IMPACT AND INFLUENCE

Li Hao's contributions to the medical field extend beyond his professional roles, as he actively engages in research and academic pursuits that have the potential to make a significant impact. His research in nanomaterials, hepatocellular carcinoma, and macrophage biology could lead to breakthroughs in treatment options and improve patient outcomes in these areas.

ACADEMIC SITES

Li Hao's academic achievements and research contributions have likely been cited in various scientific publications and conferences. His interdisciplinary research in nanomaterials, hepatocellular carcinoma, and macrophage biology demonstrates his commitment to advancing medical science and contributing valuable insights to the academic community.

LEGACY AND FUTURE CONTRIBUTIONS

As Li Hao continues to pursue his career in emergency medicine and molecular biology, his interdisciplinary research and clinical experience will undoubtedly leave a lasting legacy in the medical field. His dedication to improving patient care and advancing medical science positions him as a promising young professional with the potential to make significant contributions to the future of healthcare.

NOTABLE PUBLICATIONS

Nanomaterials modulate tumor-associated macrophages for the treatment of digestive system tumors.Ā  2024

Glutamate Chemical Exchange Saturation Transfer (GluCEST) MRI to Evaluate the Rapid Antidepressant Effects of Ketamine in the Hippocampus of Rat Depression Model. 2024 (1)

Preclinical multi-physiologic monitoring of immediate-early responses to diverse treatment strategies in breast cancer by optoacoustic imaging. 2024

Glutamate alterations in the premature infant brain during different gestational ages with glutamate chemical exchange saturation transfer imaging: a pilot study. 2023 (1)

Xenon inhalation attenuates neuronal injury and prevents epilepsy in febrile seizure Sprague-Dawley pups. 2023 (1)

 

Dr. Linxi Zhu – Cancer Genetics – Best Researcher Award

Posted on by Pencis

Dr. Linxi Zhu - Cancer Genetics - Best Researcher Award

Nanjing Drum Tower Hospital - China

Author Profile

Scopus

EARLY ACADEMIC PURSUITS:

Linxi Zhu commenced her academic journey at Nanjing University, where she pursued a Bachelor's degree from July 2015 to June 2020. Following her undergraduate studies, she continued her academic pursuit at the same institution, earning a Master's degree from July 2020 to June 2021. Linxi Zhu then advanced further in her educational journey, undertaking a Ph.D. program at Nanjing University from July 2021 to June 2023.

PROFESSIONAL ENDEAVORS:

Since September 2023, Linxi Zhu has been serving as a Surgeon at Nanjing Drum Tower Hospital, marking a significant transition from academic pursuits to practical application in the field of surgery.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER GENETICS :

Linxi Zhu's research has made notable contributions to the field of cancer genetics. Notably, her work titled "Loss of Claudin-1 incurred by DNMT aberration promotes pancreatic cancer progression" (published in Cancer Lett., 2024) sheds light on the molecular mechanisms underlying pancreatic cancer progression. Additionally, she has contributed to the development and validation of a nomogram for predicting post-operative abdominal infection in patients undergoing pancreaticoduodenectomy, as well as exploring the role of preoperative biliary drainage in postoperative outcomes after pancreaticoduodenectomy.

IMPACT AND INFLUENCE:

Zhu's research impact extends beyond pancreatic cancer, with contributions to the field of intrahepatic cholangiocarcinoma. Her collaborative work on high endothelial venule as a prognostic immune-related biomarker in patients with resected intrahepatic cholangiocarcinoma (published in Cell Prolif., 2023) underscores her diverse research interests.

ACADEMIC CITES:

Linxi Zhu has published in reputable journals, evident from her publications in Cancer Lett., Clin Chim Acta, Gland Surg, Cell Prolif., and Front Oncol. The citations received for her work demonstrate its scholarly significance and recognition within the academic community.

LEGACY AND FUTURE CONTRIBUTIONS:

Zhu's legacy lies in her comprehensive understanding of pancreatic cancer and related surgical interventions. Her research on individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in unresectable pancreatic cancer showcases innovative approaches. Looking forward, Linxi Zhu is poised to contribute further to the field, leaving a lasting impact on surgical and oncological research.

NOTABLE PUBLICATIONS

Development and validation of a nomogram for predicting post-operative abdominal infection in patients undergoing pancreaticoduodenectomy. 2022

Loss of Claudin-1 incurred by DNMT aberration promotes pancreatic cancer progression. 2024